Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2018 2
2019 4
2020 9
2021 8
2022 9
2023 5
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Bmal1 Regulates Prostate Growth via Cell-Cycle Modulation.
Ueda M, Kono J, Sengiku A, Nagumo Y, Mathis BJ, Shimba S, Taketo MM, Kobayashi T, Ogawa O, Negoro H. Ueda M, et al. Among authors: nagumo y. Int J Mol Sci. 2022 Sep 24;23(19):11272. doi: 10.3390/ijms231911272. Int J Mol Sci. 2022. PMID: 36232573 Free PMC article.
[Rare Cancers in the Genitourinary Tract].
Nagumo Y, Kandori S, Nishiyama H. Nagumo Y, et al. Gan To Kagaku Ryoho. 2020 Jul;47(7):1026-1030. Gan To Kagaku Ryoho. 2020. PMID: 32668844 Japanese.
Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial.
Kimura T, Ishikawa H, Nagumo Y, Sekino Y, Kageyama Y, Ushijima H, Kawai T, Yamashita H, Azuma H, Nihei K, Takemura M, Hashimoto K, Maruo K, Tsuzuki T, Nishiyama H; BPT-ART Investigators Group. Kimura T, et al. Among authors: nagumo y. Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):644-651. doi: 10.1016/j.ijrobp.2023.05.013. Epub 2023 May 15. Int J Radiat Oncol Biol Phys. 2023. PMID: 37196834 Free article. Clinical Trial.
ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.
Tanaka K, Kandori S, Sakka S, Nitta S, Tanuma K, Shiga M, Nagumo Y, Negoro H, Kojima T, Mathis BJ, Shimazui T, Watanabe M, Sato TA, Miyamoto T, Matsuzaka T, Shimano H, Nishiyama H. Tanaka K, et al. Among authors: nagumo y. Oncol Rep. 2022 Feb;47(2):23. doi: 10.3892/or.2021.8234. Epub 2021 Nov 29. Oncol Rep. 2022. PMID: 34841437 Free PMC article.
Clinicopathological features of adrenal malignancies: Analysis of hospital-based cancer registry data in Japan.
Chihara I, Nagumo Y, Kandori S, Kojo K, Sano K, Hamada K, Tanuma K, Tsuchiya H, Shiga M, Sakka S, Kimura T, Kawahara T, Hoshi A, Negoro H, Kojima T, Bryan MJ, Okuyama A, Higashi T, Nishiyama H. Chihara I, et al. Among authors: nagumo y. Int J Urol. 2022 Nov;29(11):1331-1337. doi: 10.1111/iju.14996. Epub 2022 Aug 17. Int J Urol. 2022. PMID: 35976672
41 results